Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - Wellvalue Healthcare Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted by the Australian Parliament to regulate the quality, safety, and efficacy of therapeutic goods, including medicines, medical devices, and blood products. One of the primary objectives of the Act is to ensure that therapeutic goods available in Australia are safe and effective for use, and this includes the regulation of the entities allowed to manufacture these goods. In 2012, the Therapeutic Goods Administration, acting under the authority delegated by the Secretary, revoked the licence of Wellvalue Healthcare Pty Ltd to manufacture therapeutic goods under paragraph 41(1)(d) of the Act. This revocation was made at the request of the manufacturer itself, underscoring the Act's role in maintaining the integrity of the therapeutic goods market by removing entities that no longer meet the regulatory standards.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of entities and individuals involved in the manufacture, supply, import and export of therapeutic goods in Australia. This includes companies, corporations, partnerships, and individuals who are engaged in activities related to therapeutic goods. The Act has a nationwide reach, being a Commonwealth Act, and therefore applies across all states and territories within Australia. The Act provides a regulatory framework for ensuring the safety, quality, and efficacy of therapeutic goods, which include medicines, medical devices, blood and blood components, tissues, and vaccines. The Act establishes a licensing system for manufacturers and importers of therapeutic goods, and mandates that therapeutic goods must meet specific standards and comply with applicable requirements before they can be supplied in Australia. While the Act broadly applies to all entities involved in the supply of therapeutic goods, it does provide for certain exclusions and exemptions. For example, the Act does not apply to therapeutic goods that are intended for personal use or for use in a clinical trial. Additionally, the Act provides for a range of subordinate instruments to be made under its authority, which may further extend or restrict its application. The revocation of a manufacturer's licence, as outlined in the Gazette publication, is an example of how the Act can be enforced to ensure compliance with its provisions.

Key Provisions

The Therapeutic Goods Act 1989 provides several mechanisms for the regulation of therapeutic goods, including the ability to revoke manufacturing licenses. In this instance, the Secretary has revoked the licence held by Wellvalue Healthcare Pty Ltd, manufacturer number MI-28102004-LI-000091-1, situated at 217 Flinders Street, Adelaide, South Australia, 5000, as stated in section 41(1)(d) (paragraph 41(1)(d)). This revocation was conducted at the request of the manufacturer itself, which indicates a voluntary surrender of their manufacturing licence. Entities like Wellvalue Healthcare Pty Ltd, who hold a licence to manufacture therapeutic goods, are subject to various obligations under the Act. These include ensuring that their manufacturing processes comply with the quality standards set forth in the Therapeutic Goods Regulations 1990, maintaining records of their manufacturing activities, and reporting any adverse events related to their products to the Therapeutic Goods Administration. The revocation of their licence means that they are no longer authorised to manufacture therapeutic goods, and they must cease all manufacturing activities immediately. Failure to comply with the requirements of the Therapeutic Goods Act 1989 can result in serious consequences. For instance, operating without a valid manufacturing licence is an offence under section 20 of the Act, and can result in significant penalties. The maximum penalty for an individual is $216,000 or imprisonment for five years, or both, while the maximum penalty for a corporation is $1,080,000 or imprisonment for fifty penalty units, or both (section 30A). Additionally, continued operation after licence revocation may lead to further penalties or legal action under other relevant sections of the Act. In summary, the Therapeutic Goods Act 1989 provides a robust framework for the regulation of therapeutic goods in Australia, with the power to revoke manufacturing licences where necessary. The revocation of Wellvalue Healthcare Pty Ltd's licence serves as a reminder of the importance of compliance with the Act's requirements, and the serious consequences that can result from non-compliance. It is imperative for entities involved in the manufacture of therapeutic goods to understand and adhere to their obligations under the Act to avoid any potential legal repercussions.